Literature DB >> 6427830

Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects.

R Weizman, A Weizman, S Tyano, G Szekely, B A Weissman, Y Sarne.   

Abstract

Basal morning humoral (H)-endorphin blood levels were assessed in ten autistic patients, 12 chronic schizophrenic patients and 11 healthy control subjects. Four autistic patients and four schizophrenic patients were drug free for at least 6 months while all other psychiatric patients were under treatment with antidopaminergic agents. Significantly reduced opioid levels were observed in the autistic group (827 +/- 103 vs 1121 +/- 75 pg-eq/ml, P less than 0.025), although the difference was actually only 26% of the control mean. A similar tendency toward low H-endorphin levels was also observed in the schizophrenic patients; however this difference was not significant (919 +/- 129 vs 1121 +/- 75 pg-eq/ml; NS). No significant difference was obtained between subjects suffering from the two psychiatric disorders (827 +/- 103 vs 919 +/- 129 pg-eq/ml; NS). Various interpretations of the decreased secretion of H-endorphin are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427830     DOI: 10.1007/bf00427687

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  A stable enkephalin-like immunoreactive substance in human CSF.

Authors:  Y Sarne; R Azov; B A Weissman
Journal:  Brain Res       Date:  1978-08-04       Impact factor: 3.252

2.  Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.

Authors:  H M Emrich; V Höllt; M Bergmann; W Kissling; W Schmid; D V Zerssen; A Herz
Journal:  Adv Biochem Psychopharmacol       Date:  1980

3.  C.S.F. beta-endorphin in schizophrenia.

Authors:  W Domschke; A Dickschas; P Mitznegg
Journal:  Lancet       Date:  1979-05-12       Impact factor: 79.321

4.  Synthetic enkephalin analogue in treatment of schizophrenia.

Authors:  A Jørgensen; R Fog; B Veilis
Journal:  Lancet       Date:  1979-04-28       Impact factor: 79.321

5.  Humoral endorphin: a new endogenous factor with opiate-like activity.

Authors:  Y Sarne; B A Weissman; O Keren; G Urca
Journal:  Life Sci       Date:  1981-02-09       Impact factor: 5.037

6.  beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects.

Authors:  H Lehmann; N P Nair; N S Kline
Journal:  Am J Psychiatry       Date:  1979-06       Impact factor: 18.112

7.  Increased CSF levels of endorphines in chronic psychosis.

Authors:  L Terenius; A Wahlström; L Lindström; E Widerlöv
Journal:  Neurosci Lett       Date:  1976-10       Impact factor: 3.046

8.  Electroconvulsive shock (ECS) and H-endorphin-induced analgesia: unconventional interactions with naloxone.

Authors:  G Urca; A Harouni; Y Sarne
Journal:  Eur J Pharmacol       Date:  1982-07-09       Impact factor: 4.432

9.  Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers.

Authors:  D Naber; D Pickar; R M Post; D P Van Kammen; R N Waters; J C Ballenger; F K Goodwin; W E Bunney
Journal:  Am J Psychiatry       Date:  1981-11       Impact factor: 18.112

10.  Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report.

Authors:  C A Tamminga; P J Tighe; T N Chase; E G DeFraites; M H Schaffer
Journal:  Arch Gen Psychiatry       Date:  1981-02
View more
  9 in total

1.  Brief report: a double-blind study of naltrexone in infantile autism.

Authors:  M Leboyer; M P Bouvard; J M Launay; F Tabuteau; D Waller; M Dugas; B Kerdelhue; P Lensing; J Panksepp
Journal:  J Autism Dev Disord       Date:  1992-06

2.  Brief report: plasma beta-endorphin and cortisol levels in autistic patients.

Authors:  C A Sandman; J L Barron; A Chicz-DeMet; E M DeMet
Journal:  J Autism Dev Disord       Date:  1991-03

3.  Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism.

Authors:  I Nir; D Meir; N Zilber; H Knobler; J Hadjez; Y Lerner
Journal:  J Autism Dev Disord       Date:  1995-12

4.  Further speculations on possible dopamine-opioid link in autism.

Authors:  R Sandyk
Journal:  J Autism Dev Disord       Date:  1986-03

Review 5.  μ opioid receptor, social behaviour and autism spectrum disorder: reward matters.

Authors:  Lucie P Pellissier; Jorge Gandía; Thibaut Laboute; Jérôme A J Becker; Julie Le Merrer
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

6.  Brain opioids and autism: an updated analysis of possible linkages.

Authors:  T L Sahley; J Panksepp
Journal:  J Autism Dev Disord       Date:  1987-06

Review 7.  [Autism and pain - a literature review].

Authors:  Amandine Dubois; Cécile Rattaz; René Pry; Amaria Baghdadli
Journal:  Pain Res Manag       Date:  2010 Jul-Aug       Impact factor: 3.037

8.  Reduced cerebrospinal fluid B-endorphin levels in Rett syndrome.

Authors:  A R Genazzani; M Zappella; A Nalin; Y Hayek; F Facchinetti
Journal:  Childs Nerv Syst       Date:  1989-04       Impact factor: 1.475

9.  Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder.

Authors:  Sylvie Tordjman; George M Anderson; Michel Botbol; Sylvie Brailly-Tabard; Fernando Perez-Diaz; Rozenn Graignic; Michèle Carlier; Gérard Schmit; Anne-Catherine Rolland; Olivier Bonnot; Séverine Trabado; Pierre Roubertoux; Guillaume Bronsard
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.